$473 Million is the total value of COMMODORE CAPITAL LP's 24 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRUS | Buy | MERUS N V | $59,221,000 | +23.3% | 2,615,762 | +44.0% | 12.52% | +16.7% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $48,518,000 | +32.0% | 1,594,932 | +32.6% | 10.26% | +24.9% |
| COGT | Buy | COGENT BIOSCIENCES INC | $44,601,000 | +70.1% | 4,944,708 | +41.2% | 9.43% | +61.0% |
| BLU | Sell | BELLUS HEALTH INC NEW | $41,393,000 | +6.7% | 4,479,784 | -20.5% | 8.75% | +1.0% |
| CYTK | Buy | CYTOKINETICS INC | $35,111,000 | +11.6% | 893,646 | +4.6% | 7.42% | +5.6% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $33,652,000 | -15.7% | 2,410,622 | +4.1% | 7.12% | -20.2% |
| KURA | Buy | KURA ONCOLOGY INC | $33,480,000 | +168.1% | 1,826,491 | +135.2% | 7.08% | +153.8% |
| ISEE | Buy | IVERIC BIO INC | $23,184,000 | -37.8% | 2,409,961 | +8.8% | 4.90% | -41.1% |
| TCDA | Buy | TRICIDA INC | $19,635,000 | +36.9% | 2,028,453 | +16.3% | 4.15% | +29.6% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $18,959,000 | +7.8% | 1,638,609 | +72.2% | 4.01% | +2.0% |
| CBAY | CYMABAY THERAPEUTICS INC | $16,929,000 | -5.1% | 5,738,500 | 0.0% | 3.58% | -10.2% | |
| STSA | SATSUMA PHARMACEUTICALS INC | $15,365,000 | +8.9% | 3,711,286 | 0.0% | 3.25% | +3.1% | |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $14,526,000 | +76.8% | 538,812 | +123.4% | 3.07% | +67.4% |
| DAWN | New | DAY ONE BIOPHARMACEUTICALS I | $13,240,000 | – | 739,661 | +100.0% | 2.80% | – |
| VTGN | Buy | VISTAGEN THERAPEUTICS INC | $11,483,000 | -8.3% | 13,049,079 | +29.2% | 2.43% | -13.2% |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $11,004,000 | – | 312,533 | +100.0% | 2.33% | – |
| KPTI | Sell | KARYOPHARM THERAPEUTICS INC | $8,730,000 | -66.7% | 1,935,609 | -45.6% | 1.85% | -68.5% |
| CELC | CELCUITY INC | $8,376,000 | -2.7% | 920,464 | 0.0% | 1.77% | -7.9% | |
| RZLT | New | REZOLUTE INC | $3,908,000 | – | 1,210,000 | +100.0% | 0.83% | – |
| IMUX | IMMUNIC INC | $3,099,000 | -69.3% | 893,013 | 0.0% | 0.66% | -70.9% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $3,076,000 | -33.2% | 312,553 | 0.0% | 0.65% | -36.8% | |
| BLSA | BCLS ACQUISITION CORP | $2,475,000 | +0.3% | 250,000 | 0.0% | 0.52% | -5.1% | |
| Sell | TENAYA THERAPEUTICS INC | $2,014,000 | -66.7% | 357,699 | -30.4% | 0.43% | -68.5% | |
| IVA | Sell | INVENTIVA SAads | $995,000 | -66.8% | 175,500 | -33.2% | 0.21% | -68.6% |
| MREO | Exit | MEREO BIOPHARMA GROUP PLCads | $0 | – | -1,954,970 | -100.0% | -0.49% | – |
| PMVP | Exit | PMV PHARMACEUTICALS INC | $0 | – | -125,000 | -100.0% | -0.58% | – |
| DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -305,125 | -100.0% | -0.66% | – |
| GNCA | Exit | GENOCEA BIOSCIENCES INC | $0 | – | -3,079,756 | -100.0% | -0.86% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -331,886 | -100.0% | -1.76% | – |
| CCCC | Exit | C4 THERAPEUTICS INC | $0 | – | -481,094 | -100.0% | -2.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.